We would like to share ideas on the publication "Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung 1 ". The article explored the potential relationship ...

Tarlatamab is a bispecific T-cell engager (BiTE) that binds to delta-like ligand-3 (DLL3) on small cell lung cancer (SCLC) cells and cluster of differentiation-3 on T cells, thereby delivering ...

Vergent Bioscience, a clinical-stage biotechnology company developing tumor targeted imaging agents, announced new data being presented at the 2025 American ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.

The mammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug Administration-approved for advanced pancreatic neuroendocrine neoplasms (pNENs), yet resistance is common, ...

The Toronto Blue Jays were swept in a doubleheader on Sunday by the New York Yankees, falling to 13-15. After starting out 12-8, Toronto has now lost seven of its last eight games. The Jays were ...

For the organoid experiment, TRACERx patient–derived lung tumor organoid cells were cultured with human myeloid cells isolated from the lungs of immunodeficient mice engrafted with human TET2 ...

Olivia Williams opened up about her harrowing journey with pancreatic cancer, revealing she experienced years of misdiagnoses, dismissals by doctors.

A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...

Checkpoint inhibitors have broadened treatment options for a growing list of tumor types, from melanoma to lung cancer. Very few high-grade neuroendocrine carcinomas respond to the drugs.

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo – – ...

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors ...